SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance

Delivered ~15% WW revenue growth and ~178% increase in adjusted EBITDA ~19% increase in U.S. physician base

Second Quarter 2026 Financial Highlights (all comparisons are to the prior year period) * Worldwide revenue of $56.0 million, representing growth of 15.2% * U.S. revenue of $53.2 million, representing growth of 14.7% * Gross margin of 79.5% * Net loss of $4.1 million, representing an improvement of 33.6% * Positive adjusted EBITDA of $2.8 million, an improvement of 178.0% * Positive cash from operations of $0.8 million * $145.9 million in cash and equivalents, representing a sequential increase of $1.3 million Recent Operational Highlights (any comparisons are to the prior year period) * 1,715 active U.S. physicians, representing growth of 19% * $2.2 million in trailing 12-month average revenue per territory, representing an increase of 5% * In June, submitted 510(k) application for the third-breakthrough device targeting one of the largest unmet needs in spine surgery * CMS finalized new MS-DRG family providing higher payments for complex spinal fusion procedures that incorporate iFuse Bedrock Granite in an in-patient setting, effective October 1 SANTA CLARA, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today reported financial results for the quarter ended June 30, 2026.